TAMIR BIOTECHNOLOGY, INC. (ACEL) financial statements (2020 and earlier)

Company profile

Business Address 300 ATRIUM DRIVE
SOMERSET, NJ 08873
State of Incorp. DE
Fiscal Year End July 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2013
Q2
10/31/2012
Q1
7/31/2012
Q4
4/30/2012
Q3
1/31/2012
Q2
10/31/2011
Q1
7/31/2011
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10 0
Cash and cash equivalents10 0
Prepaid expense and other current assets00 0
Other undisclosed current assets0  0
Total current assets:10 0
Noncurrent Assets
Property, plant and equipment00 0
Deferred costs 0 0
Total noncurrent assets:00 0
TOTAL ASSETS:10 0
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11 1
Accounts payable11 1
Accrued liabilities00 0
Debt 3 3
Derivative instruments and hedges, liabilities61 1
Other undisclosed current liabilities 0 1
Total current liabilities:76 5
Noncurrent Liabilities
Liabilities, other than long-term debt00 0
Accounts payable and accrued liabilities00 0
Other undisclosed noncurrent liabilities00 0
Total noncurrent liabilities:11 1
Total liabilities:76 6
Stockholders' equity
Stockholders' equity attributable to parent, including:(7)(6) (6)
Preferred stock0   
Common stock00 0
Additional paid in capital101101 101
Accumulated deficit(108)(107) (107)
Other undisclosed stockholders' equity attributable to parent0   
Total stockholders' equity:(7)(6) (6)
TOTAL LIABILITIES AND EQUITY:10 0

Income statement (P&L) ($ in millions)

1/31/2013
Q2
10/31/2012
Q1
7/31/2012
Q4
4/30/2012
Q3
1/31/2012
Q2
10/31/2011
Q1
7/31/2011
Q4
Operating expenses(0)(0) (0)
Operating loss:(0)(0) (0)
Nonoperating income (expense)
(Investment Income, Nonoperating)
 (0) 0
Interest and debt expense3(0) (0)
Net income (loss):3(0) (0)
Other undisclosed net income (loss) attributable to parent(4)(0) 1
Net income (loss) available to common stockholders, diluted:(0)(0) 1

Comprehensive Income ($ in millions)

1/31/2013
Q2
10/31/2012
Q1
7/31/2012
Q4
4/30/2012
Q3
1/31/2012
Q2
10/31/2011
Q1
7/31/2011
Q4
Net income (loss):3(0) (0)
Comprehensive income (loss), net of tax, attributable to parent:3(0) (0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: